This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hegi, M. E. Articles by Aguzzi, A. Search for Related Content PubMed PubMed Citation Articles by Hegi, M. E. Articles by Aguzzi, A.

p53 Transdominance But No Gain of Function in Mouse Brain Tumor Model¹

Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland [M. E. H., M-F. H.], Institute of Neuropathology, University Hospital of Zurich, 8091 Zurich, Switzerland [M. E. H., M. A. K., D. R., A. A.], and Oncology Department, Novartis, 4002 Basel, Switzerland [P. C.]

Although p53 mutations in tumors typically result in loss of transactivation of p53 target genes some mutants display gain-of-function activity. The latter has important implications for the design of rational cancer therapy. We previously described a germ-line p53 mutation (deletion of codon 236, Y236) associated with a familial brain tumor syndrome. To determine whether this tissue-specific tumor predisposition reflects a gain-of-function activity of Y236 or an effect of genetic background we have developed a mouse brain tumor model. Primary neuroectodermal cells deficient for p53 (+/- or -/-) and transduced with Y236 using a retroviral vector were transplanted into the brain of adult wild-type mice. This neurografting paradigm circumvents the problem of early lethal tumors at extracerebral sites associated with germ-line p53 deficiency. Brain tumors arising in this mouse model were highly invasive, reflecting an important feature of the human disease. Tumors arose from p53^+/- cells only when transduced with Y236. In keeping with in vitro data showing that Y236 has dominant-negative activity, these tumors retained the endogenous wild-type p53 allele but accumulated high levels of Y236. However, the presence of Y236 in transplanted p53^-/- cells had no effect on the tumor frequency, 15% versus 27% without the mutant. In conclusion, Y236 is transdominant but exerts no gain-of-function activity mediating a more penetrant tumor phenotype.